# Improving exercise rehabilitation efficacy and outcomes in Veterans with peripheral artery disease: Targeting oxidative stress and inflammation

> **NIH VA IK2** · VA SALT LAKE CITY HEALTHCARE SYSTEM · 2024 · —

## Abstract

Peripheral artery disease (PAD) is a debilitating atherosclerotic disease caused by plaque development in the
arteries leading to diminished skeletal muscle blood flow, oxygen delivery, and metabolic dysfunction during
ambulation causing marked exercise intolerance. Veterans have a disproportionate risk of developing PAD
compared to the general population because of higher levels of smoking, hypertension, diabetes, and obesity.
Worryingly, the mortality rate for PAD in Veterans (~30%) is nearly double that of the general population.
Currently, the best treatment of PAD is exercise rehabilitation, however, issues with patient motivation and pain
reduce the effectiveness of this treatment. There is a pressing, and unmet need to identify the sites and
underlying mechanisms of the systemic dysfunction leading to exercise intolerance induced by PAD. Oxidative
stress and inflammation play important roles in the development and progression of PAD. Critically, the
peripheral vasculature (diminished blood flow) and mitochondria (diminished respiration) are primary
determinants/mechanisms responsible for exercise intolerance in health and disease that are particularly
vulnerable to elevations in oxidative stress and inflammation, making these likely sites of systemic dysfunction
leading to exercise intolerance in Veterans with PAD. Any vascular or mitochondrial dysfunction would further
augment oxidative stress and inflammation initiating a vicious cycle. It is our central hypothesis that increased
endogenous antioxidant capacity and diminished inflammation will improve oxygen delivery and utilization during
exercise, thus, increasing the efficacy of exercise rehabilitation due to increased adherence and exercise
capacity. To test this hypothesis, we will utilize the naturally-derived Nuclear Factor Erythroid-2-like 2 (Nrf2; the
“master regulator of antioxidant enzymes”) activator, PB125, to stimulate induction of endogenous antioxidants
and decrease the activity of inflammatory pathways. Veterans with PAD will be randomly assigned to receive
either PB125 or Placebo supplementation. Each Veteran will undergo three phases of testing: 1) baseline, 2)
post 1 month of supplement loading, and 3) post 12 weeks of exercise rehabilitation with continued
supplementation. Functional capacity and cognitive function (Aim 1), Vascular function and exercising
hemodynamics (Aim 2), and in vivo and ex vivo mitochondrial respiration (Aim 3) will be assessed each phase.
Monthly assessments of functional capacity, behavioral regulation, quality of life, and physical activity will track
improvements across the trial. At the conclusion of these studies, we will have expanded our knowledge of the
mechanisms underlying exercise intolerance in Veterans suffering from PAD, and, more importantly from a
clinical perspective, provided insight into a potential novel therapeutic treatment to improve exercise
rehabilitation efficacy for this population. It is anticipated this advancemen...

## Key facts

- **NIH application ID:** 10869935
- **Project number:** 5IK2RX003913-02
- **Recipient organization:** VA SALT LAKE CITY HEALTHCARE SYSTEM
- **Principal Investigator:** Jesse Charles Craig
- **Activity code:** IK2 (R01, R21, SBIR, etc.)
- **Funding institute:** VA
- **Fiscal year:** 2024
- **Award amount:** —
- **Award type:** 5
- **Project period:** 2023-07-01 → 2028-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10869935

## Citation

> US National Institutes of Health, RePORTER application 10869935, Improving exercise rehabilitation efficacy and outcomes in Veterans with peripheral artery disease: Targeting oxidative stress and inflammation (5IK2RX003913-02). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10869935. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*